Stifel analyst Alex Thompson raised the firm’s price target on Argenx to $478 from $471 and keeps a Buy rating on the shares. Thompson thinks that the ADHERE Ph3 readout in CIDP is likely to succeed, representing the next important step in the efgartigimod label expansion story adding support to the Argenx Bull Case into additional 2H23 catalysts, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARGX:
- Piper recommends ‘down market cap’ biotech exposure for 2023
- Argenx price target raised to EUR453 at Goldman Sachs
- argenx Appoints Ana Cespedes to Board of Directors
- argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
- Halozyme price target raised to $68 from $55 at Benchmark